he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
- 2022-04-252013年国际性抗癫痫联合会抗癫痫药使用指南
- 高血压杀了很多人,降压药真的停不下来
- 糖尿病小传教育一目了然
- 专注于小核酸药物的佑嘉生物完成A几千万元融资,渤溢基金领投,凯成资本担任首席财务顾问
- 仙鹤草的功效是什么?
- FDA批准Aptiom用于治疗患者癫痫发作
- 感觉肿块,增生还是癌症?
- 外阴肿痛不好意思看?说明很受伤!
- 你知道吗?快看护理知识!
- 抗癫痫药物预防新发癫痫:任重而道远
- 厕所会对健康造成这样的伤害
- 月经期间能喝茶吗? 女性月经期间能喝茶吗?
- 怀孕期间总是感到疼痛。发生了什么事?看完这篇文章,我相信你会明白的。
- 月经不调的危害最严重,可导致子宫内膜癌!
- 内陷困扰及治疗方案
- 月经期间预防什么,避免细菌感染
- 输卵管有话要说,耐心看完这些话
- 溢液是怎么回事?
- JAMA Neurology:左乙拉西坦对阿尔茨海默病患者的认知功能有影响,不伴有癫痫活动
- 【预约直播】铿锵的论道 不炎,越来越多--「郁金香论坛」学术沙龙即将举行
- 前沿资讯 | 测量体温可以检测癌症吗?RUDN大学最新研究发布!
- 非淋性尿道炎症状 非淋性尿道炎怎么办?
- 精子能吃吗? 子的好处
- 第一次同房失败,怎么治疗?
- 屁股真的越翘越好吗?不良姿势造成危害,骨盆前倾需要纠正
- 脑膜炎球菌疫苗MenQuadfi欧盟批准
- 世界妇科内部会议(ISGE)
- Eur Respir J:评估慢性支气管炎和危险因素
- 《中国慢性疾病防治基层精神科诊疗手册:神经病学分册》定稿出版
- 男人癫痫病的怎么治疗
- 招致癫痫病发病原因
- 三叉神经诱因术治疗难治性癫痫安全有效
- 欧洲议会扩展批准优时比抗癫痫药物 Vimpat 用于儿童患者
- 20130730云南养生会:沈洪俊话说癫痫病的早期症状
- 同道分享的确诊:花了三个星期才明确诊断
- 苏州举办-药企实验室(研发/QC)法规管理与 ICH 指南 及药典最新进展」研修班
- 癫痫病癫痫时有哪些症状
- 用药癫痫病最佳
- 卫材在俄罗斯问世癫痫新药Fycompa
- Circ ep:心电图机自动诊断可能漏诊外QTc延长者
- 儿童癫痫病的发病病征